Abstract:R ed blood cells (RBCs) are nature’s long-circulating delivery vehicles. They possess various remarkable properties and continue to inspire the design and engineering of man-made delivery systems. Inherently suited for intravascular delivery, RBCs are intrinsically biocompatible, biodegradable, and nonimmunogenic. They form natural compartments capable of protecting encapsulated cargos, and this allows them to circulate in the bloodstream for a long period of time (up to 120 days). In addition, their semipermeable membrane affords sustained release to smallmolecule drugs, yet they are ideal for retaining large proteins while providing them access to the substrates. Delivery vehicles possessing one or several of these properties have long been desired for efficacious therapeutics. A long-sought strategy for RBC-mimicking delivery vehicles is to load natural RBCs with therapeutic agents without compromising the structural integrity and biological functions of the RBCs. Various loading techniques, including automated loading devices, have been developed to enable the encapsulation of payloads with molecular weights of over 180 kDa into RBCs with maintenance of the carriers’ biological competence. In addition to the interior of RBCs, their exterior surface has also been coupled with therapeutic molecules, either covalently or physically, for various delivery applications. These RBC-based delivery vehicles, namely carrier RBCs, have been developed for the delivery of numerous therapeutic agents, including proteins, nucleic acids, and small-molecule drugs. Several of them have entered clinical tests to treat various diseases, including cancers and enzyme deficiencies. Meanwhile, advances in molecular biology have provided unprecedented understanding of the connections between the physicochemical characteristics of RBCs and their biological functions. This understanding, in turn, has inspired researchers to model drug carriers after RBCs. Designs that mimic the physicochemical characteristics and biological functions of RBCs, particularly those that enable their passage through narrow constrictions while maintaining a long in vivo survival, have been integrated into the engineering of drug carriers and have resulted in novel delivery systems with improved drug tolerability, circulation lifetime, and efficacy. Recently, the pursuit of RBC-mimicking nanoparticles led us to develop an intriguing approach for functionalizing synthetic nanoparticles with natural RBC membranes. In this approach, we first collected intact cellular membranes and then coated them onto polymeric nanoparticle cores, such as those made from poly(lactic-co-glycolic acid) (PLGA); this resulted in red-blood-cell-membrane–coated nanoparticles (RBC-NPs; Figure 1). Our aim was to fabricate cellmimicking nanoparticles through a top-down approach that bypassed the labor-intensive processes of protein identification, purification, and conjugation. The natural membranes also provide a bilayered medium for transmembrane protein anchorage while preventing common chemical modifications that could compromise the integrity and functionalities of these proteins. The independent preparation of cellular membranes and particle cores before coating offers a new level of engineering flexibility toward highly functional biomimetic nanoparticles. Since their initial development, RBC-NPs have provided an unprecedented capability for harnessing the natural functionalities of native cells that would otherwise be difficult to replicate. They have since inspired us to develop novel nanotherapeutics for better disease intervention. In this Perspective, we review our recent progress in developing RBC-NPs for three distinct biomedical applications: long-circulating nanocarriers for drug delivery, biomimetic nanosponges for detoxification, and nanotoxoids for safe and effective toxin vaccination.

Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes

Comparative Study of Nanoparticle Blood Circulation after Forced Clearance of Own Erythrocytes (Mononuclear Phagocyte System-Cytoblockade) or Administration of Cytotoxic Doxorubicin- or Clodronate-Loaded Liposomes

Engineering red‐blood‐cell‐membrane–coated nanoparticles for broad biomedical applications

Surface loading of nanoparticles on engineered or natural erythrocytes for prolonged circulation time: strategies and applications

Some Preliminary Results to Eradicate Leukemic Cells in Extracorporeal Circulation by Actuating Doxorubicin-Loaded Nanochains of Fe3O4 Nanoparticles

Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing

Gadofullerene nanoparticles for robust treatment of aplastic anemia induced by chemotherapy drugs

Some Preliminary Results to Eradicate Leukemic Cells in Extracorporeal Circulation by Actuating Doxorubicin-Loaded Nanochains of Fe<sub>3</sub>O<sub>4</sub> Nanoparticles

Noninvasive monitoring of nanoparticle clearance and aggregation in blood circulation by in vivo flow cytometry

Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles

Cell Membrane-Camouflaged Nanocarriers with Biomimetic Deformability of Erythrocytes for Ultralong Circulation and Enhanced Cancer Therapy

Prolonged blood circulation outperforms active targeting for nanocarriers-mediated enhanced hepatocellular carcinoma therapy in vivo

Microfluidic Electroporation-Facilitated Synthesis of Erythrocyte Membrane-Coated Magnetic Nanoparticles for Enhanced Imaging-Guided Cancer Therapy

Effect of increasing liver blood flow on nanodrug clearance by the liver for enhanced antitumor therapy.

Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy.

Alternating Stealth Polymer Coatings Between Administrations Minimizes Toxic and Antibody Immune Responses Towards Nanomedicine Treatment Regimens.

A Pleiotropic Nanomedicine Mitigates Splenic Hyperplasia, Ineffective Erythropoiesis, G6PDH Anomaly through Redox Buffering in Preclinical Mice Model

Recent advances in erythrocyte membrane-camouflaged nanoparticles for the delivery of anti-cancer therapeutics

Red‐Blood‐Cell‐Membrane‐Coated Metal‐Drug Nanoparticles for Enhanced Chemotherapy

Altering the response of intracellular reactive oxygen to magnetic nanoparticles using ultrasound and microbubbles

Mixed-charge nanoparticles for long circulation, low reticuloendothelial system clearance, and high tumor accumulation.